Core Viewpoint - Polyrizon Ltd. has received approval from the Nasdaq Hearings Panel to continue its listing on the Nasdaq Capital Market, following a plan to address concerns regarding its capital structure and compliance with listing standards [1][3]. Group 1: Nasdaq Listing and Compliance - The Nasdaq Listing Qualifications Department previously issued a public interest determination under Listing Rule 5101 due to the company's issuance of securities in a private placement, particularly concerning Series A warrants [2]. - A hearing was held on June 26, 2025, where Polyrizon presented its plan to avoid complex financing instruments in future capital-raising activities [3]. - The Panel's determination on July 9, 2025, allows the company to maintain its listing, contingent upon regaining compliance with the Minimum Bid Price Rule by October 17, 2025 [3]. Group 2: Financial Position and Capital Structure - Following the private placement, the company reported a cash balance of approximately $15.68 million, and all warrants issued in the transaction have been exercised, simplifying its capital structure [4]. - The elimination of a significant source of potential dilution is expected to enhance long-term shareholder value [4]. Group 3: Internal Controls and Future Plans - The company is implementing a formal internal control framework to govern future securities issuances and ensure compliance with Nasdaq standards, including enhanced oversight and quarterly internal compliance reviews [5]. Group 4: Company Overview - Polyrizon is a development stage biotech company focused on innovative intranasal hydrogels that create a barrier against viruses and allergens in the nasal cavity [5]. - The proprietary Capture and Contain hydrogel technology is designed to function as a "biological mask," and the company is also developing the Trap and Target technology for nasal delivery of active pharmaceutical ingredients [5].
Polyrizon Retains Nasdaq Listing Following Hearings Panel